Navigation Links
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units

DUBLIN, Jan. 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced an updated business structure for its U.S. Specialty Brands business designed to maximize the Company's newly strengthened position in key therapeutic areas and position it for continued long-term growth.

Under its new structure, Actavis' U.S. Specialty Brands business has been refocused as four business units - Women's Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations.  The Company announced the appointment of Herm Cukier to lead the U.S. Specialty Brands Women's Healthcare category, Charles Sabino, Jr., to lead the U.S. Specialty Brands Urology and GI therapeutic category, and Thomas Griffin, Jr., to lead the Business Operations team.  The Company is actively engaged in planning efforts related to the leadership of the U.S. Specialty Brands Dermatology and Established Brands business.  The four business unit leaders will report to Tim Callahan, Senior Vice President, Commercial Operations, who reports to Fred Wilkinson, President, Actavis Specialty Brands. 

"The significant increase in size and complexity of our U.S. Specialty Brands business, following the acquisition of Warner Chilcott last year, demands that we have the right structure and exceptional leadership team in place to drive our continued commercial success in the future," said Mr. Wilkinson. "We believe this business unit structure will provide the most effective way to manage our larger portfolio, provide deeper product and customer insights and deliver the necessary focus to drive continued growth in each therapeutic category within our U.S. Specialty Brands business." 

U.S. Women's Health

Actavis' U.S. Women's Health business is an industry leader with over 90 percent share of voice in oral contraceptives based on IMS Audits and a robust pipeline recently bolstered with the addition of seven new development programs encompassing three near-term launches and more than 10 products in late-stage development.  As General Manager, U.S. Women's Health, Mr. Cukier joins Actavis from Bayer, where he served most recently as Vice President, Marketing and Commercial Operations for Women's Healthcare.  Prior to his time at Bayer, he held roles as President and CEO of Reverion Pharmaceuticals, a start-up biotech company, General Manager at Schering Plough and Chief Marketing Officer at Organon.  Earlier in his career Mr. Cukier held positions of increasing commercial responsibility at Bristol Myers Squibb and Pfizer, and he holds a BSE Degree in Bioengineering from the University of Pennsylvania and a MBA in Marketing and International Business from Columbia Business School.  Mr. Cukier adds to Actavis' extensive knowledge of the Women's Health market and brings an exceptional background in U.S. and global commercialization to the Actavis organization. 

U.S. Urology & Gastroenterology

Actavis' growing Urology business markets six products in the U.S., including Rapaflo® Androderm® and Enablex®.  The Company's Gastroenterology business in the U.S. is led by the Delzicol® and Asacol HD® franchise of products.  As General Manager, U.S. Urology and Gastroenterology, Mr. Sabino joins Actavis from Aptalis Pharma, where he most recently served as Vice President, Marketing for the specialty pharmaceutical company focused on Gastroenterology and Cystic Fibrosis treatments.  Prior to his time at Aptalis, Mr. Sabino served as Chief Operating Officer for Lipose Corp., a medical device company, and as a Managing Director for Cline, Davis & Mann, the second-largest healthcare advertising agency in the United States.  Mr. Sabino also held positions of increasing responsibility within both Pfizer and Novartis, including Executive Director of the Xolair® respiratory franchise, and he has a MBA from Columbia Business School and a BS in Biology from Haverford College.  Mr. Sabino brings significant commercial expertise to Actavis' specialty brand business and provides a strong foundation of knowledge for Actavis' new Gastroenterology business.

U.S. Business Operations

Actavis' U.S. Business Operations group will be responsible for all shared commercial functions for the respective U.S. therapeutic business units, including sales operations, sales training, marketing research, sales analytics and managed markets field teams.  Mr. Griffin has been with Actavis since 2011 as VP, Sales and Operations for the U.S. Specialty Brands business.  Prior to joining Actavis, Mr. Griffin was VP, Sales for Bayer Diabetes Care from 2008 to 2010, and prior to that spent 19 years in the Pfizer sales organization in positions of increasing responsibility, culminating as Senior VP Sales for the Urology-Respiratory Therapeutic Cluster.  Mr. Griffin brings exceptional sales leadership, operations and managed markets expertise to this newly created U.S. Business Operations unit.

About Actavis

Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA. 

Actavis markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries, and operates a global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories.  Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology.  Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement

Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with financial projections; successful integration of the Warner Chilcott acquisition and the ability to recognize the anticipated synergies and benefits of the Warner Chilcott acquisition; the impact of competitive products and pricing; periodic dependence on a small number of products for a material source of net revenue or income; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; market acceptance of and continued demand for Actavis' products; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Actavis, Inc.'s periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis plc's Quarterly Report on Form 10-Q for the period ending September 30, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.


Lisa DeFrancesco
(862) 261-7152

Charlie Mayr
(862) 261-8030

David Belian
(862) 261-8141

(Logo: )

SOURCE Actavis plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis to Host 2014 Investor Meeting January 31 in New York
2. Actavis and Warner Chilcott Receive U.S. FTC Clearance for Actavis Proposed Acquisition of Warner Chilcott
3. Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast
4. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
6. Actavis Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms
7. Actavis Names James DArecca Chief Accounting Officer
8. Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition
9. Actavis Announces New Senior Unsecured Term Loan Credit and Guaranty Agreement
10. Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
11. Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share
Post Your Comments:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... Switzerland for highly sought after internships at the pre-eminent organization in global health: ... dedicated to eliminating social and health disparities. These internships are a mechanism for ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, according ... of dying in reported home fires in half. As part of Fire Prevention Week, ... property installed and maintained. , Half of home fire deaths result from fires reported ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS ... in Madrid, Spain. Representing both the USA and Sweden in the Speed and Power ... Am Front Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I ...
(Date:10/9/2015)... ... 09, 2015 , ... Prescription Hope, the fastest growing pharmacy ... to save money on the high cost of their prescription medications through their ... and families can receive their medications delivered direct from over 180 U.S.-based pharmaceutical ...
(Date:10/9/2015)... ... October 09, 2015 , ... Deadly, record-smashing ... Carolina Community Foundation (CCCF) in Columbia, South Carolina. In response, the Foundation has ... flood victims – both short and long term. 100% of monies donated will ...
Breaking Medicine News(10 mins):
... at the University of Aberdeen in the UK say in ... are linked to increased risk of asthma in kids//. The ... same team showed that low vitamin E in mothers was ... ,In this study researchers followed 1,000 children at five ...
... By performing simple clinical maneuvers to improve donor lung ... (SALT) protocol, researchers significantly increased the// number of available ... function, length of hospital stay or survival. ... 2006 of the American Journal of Respiratory and Critical ...
... in the Sun's brightness over the past millennium have ... to a review of existing results and new calculations// ... Germany. ,The review, led by Peter Foukal (Heliophysics, ... Among the coauthors is Tom Wigley of the National ...
... supplies shrink and new infectious agents threaten blood ... by implementing// transfusion alternatives in conjunction with blood ... that can be taken by individual physicians and ... for the Advancement of Blood Management's (SABM) Fifth ...
... heart attack patient, who spent nearly 2 hours in the waiting ... a coroner's jury.// ,Beatrice Vance, 49, died of a ... deviations from the standard of care that a reasonable person would ... the Vista Medical Center in Waukegan. A spokeswoman of that center ...
... city schoolgirls have been developing culturally sensitive drawings ... children are likely to take offense and react ... over traditional written descriptions of provocative social situations," ... pediatric psychologist at The Children's Hospital of Philadelphia ...
Cached Medicine News:
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Handheld Digital Retinal Camera...
Medicine Products: